A renewal and a variation are two distinct types of regulatory submissions that serve completely different purposes. A renewal extends the validity of an existing marketing authorisation, while a variation modifies the terms of an already approved authorisation. Understanding which one applies to your situation is essential for staying compliant and avoiding unnecessary delays in your regulatory submissions.
The distinction matters most in the EU, where marketing authorisations are initially granted for five years and then become subject to renewal, while any change to an approved product must go through a formal variation procedure. The sections below unpack the most common questions companies face when navigating these two processes.
What triggers the need for a renewal versus a variation?
A renewal is triggered by the expiry timeline of your marketing authorisation, not by any change to the product itself. In the EU, an initial marketing authorisation is valid for five years. Before that period ends, the marketing authorisation holder must submit a renewal application to keep the authorisation active. A variation, on the other hand, is triggered whenever you want to change something about an already approved product, whether that is the formulation, the manufacturing process, the labelling, or the approved indications.
The key distinction is this: renewals are time-driven, and variations are change-driven. If your product has not changed but your authorisation is approaching its five-year mark, you need a renewal. If your product or its conditions of approval are changing at any point during its lifecycle, you need a variation. In practice, both situations can arise simultaneously, which is why companies with older products often find themselves managing both types of regulatory submissions at once. Our regulatory services are designed to help you handle exactly these kinds of overlapping demands efficiently.
What are the different types of variation submissions?
In the EU, variations are classified into three main categories based on the significance of the change being made. The type of variation determines the procedure, the documentation required, and the timeline for regulatory review.
- Type IA variations are minor changes with a minimal impact on quality, safety, or efficacy. These are notified to the competent authority rather than formally approved, and they can often be submitted in batches. Examples include minor editorial changes to the product information or updates to the name and address of a manufacturer with no impact on the manufacturing process.
- Type IB variations are changes that are not minor but do not meet the criteria for a major variation. They require notification and implicit approval, meaning the change can be implemented if no objection is raised within a defined timeframe.
- Type II variations are major changes that could have a significant impact on quality, safety, or efficacy. These require full assessment by the competent authority before they can be implemented. Adding a new therapeutic indication or making a significant change to the manufacturing process would typically fall into this category.
Outside the EU, the classification systems differ by region, but the underlying logic is similar: the more significant the change, the more scrutiny the regulatory submission will receive. Companies operating across multiple markets need to map each change to the correct variation type in each jurisdiction to avoid compliance gaps.
How does the EU renewal process actually work?
The EU renewal process requires the marketing authorisation holder to submit a renewal application no later than six months before the authorisation expires. The application must include an updated assessment of the benefit-risk balance of the product, taking into account all post-authorisation data accumulated since the original approval or the last renewal.
The renewal dossier typically includes a consolidated list of all variations approved since the last renewal, updated product information, and a benefit-risk assessment supported by all available pharmacovigilance and clinical data. The competent authority reviews this data to confirm that the product continues to meet the standards required for approval.
Once a product has been renewed for the first time, the marketing authorisation becomes valid indefinitely, provided the marketing authorisation holder continues to comply with post-authorisation obligations. This means that after the initial renewal, companies no longer face a fixed expiry date, but they remain responsible for maintaining compliance and submitting any required variations when changes occur.
Can a variation and a renewal be submitted at the same time?
Yes, a variation and a renewal can be submitted at the same time, and in practice this is a common scenario. If a product is approaching its renewal date and the company also needs to update the product information or make a manufacturing change, both the renewal and the variation can be submitted in parallel.
In the EU, there are specific provisions that allow variations to be grouped with a renewal application under certain conditions. This can streamline the process and reduce the administrative burden of managing two separate regulatory submissions simultaneously. However, the timing needs to be carefully planned. If a variation introduces significant changes that affect the benefit-risk profile, the renewal review may need to take those changes into account, which can add complexity to the overall assessment.
Good lifecycle planning helps avoid situations where a critical variation is stuck in review at the same time a renewal deadline is approaching. Building a regulatory calendar that maps both variation timelines and renewal dates is a practical way to manage this. To learn more about how we approach lifecycle planning for our clients, visit our company page.
What happens if you submit the wrong type of application?
Submitting the wrong type of application can lead to significant delays, additional costs, and in some cases, compliance issues. If a change is submitted as a Type IA variation when it should have been classified as a Type II, the competent authority is likely to reject the application and require resubmission under the correct procedure. This resets the clock on the review timeline and can delay implementation of the change.
For renewals, missing the submission deadline is a serious problem. If the renewal application is not submitted at least six months before the authorisation expires, the authorisation may lapse, meaning the product can no longer be legally marketed. Reinstating a lapsed authorisation is significantly more complex and time-consuming than submitting a renewal on time.
Misclassifying a variation is a common source of regulatory delays, particularly for complex changes that sit on the boundary between Type IB and Type II. When in doubt, seeking regulatory advice before submission is far more efficient than correcting a misclassified application after the fact.
How Starodub supports your renewal and variation submissions
Navigating the difference between renewals and variations is straightforward in theory but can become complex quickly when you factor in multiple markets, overlapping timelines, and the evolving EU regulatory landscape. This is where we step in.
At Starodub, we provide end-to-end support for both renewal and variation regulatory submissions, including:
- Classification of changes and identification of the correct variation type across EU and international markets
- Preparation and compilation of renewal dossiers, including benefit-risk assessments and consolidated variation lists
- Lifecycle planning to align variation timelines with upcoming renewal deadlines
- Regulatory strategy advice for complex or borderline cases where misclassification risk is high
- Submission management and follow-up with competent authorities throughout the review process
With over 400 completed projects and more than 300 clients supported, we bring the experience needed to keep your products compliant and your submissions on track. If you have an upcoming renewal or a change that requires a variation, reach out to our team to discuss how we can support your regulatory strategy.
Related Articles
- How does digital transformation affect GMP compliance requirements?
- What is the difference between GMP and cGMP compliance?
- Biologics vs. Small Molecules: How Regulatory Requirements Differ
- How do breakthrough device designations accelerate regulatory approval?
- How do post-market surveillance requirements work?
This content was generated with the help of AI and it may contain mistakes
